SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor

Heng-Maillard, Marie-Amélie
Verschuur, Arnauld
Aschero, Audrey
Dabadie, Alexia
Jouve, Elisabeth
Chastagner, Pascal
Leblond, Pierre
Aerts, Isabelle
de Luca, Bénédicte
André, Nicolas
Heng‐maillard, Marie‐amélie
Luca, Bénédicte

Open link

Publication date

February 2019

DOI

10.1002/pbc.27693

Publisher

Wiley

Abstract

International audienceTo investigate the antitumor activity of a four-drug metronomic chemotherapy (MC) regimen in relapsed/progressing pediatric extracranial solid tumors (EST). The primary objective was clinical benefit (complete response /partial response/stable disease [SD]) after two cycles of therapy (four months)

Extracted data

We use cookies to provide a better user experience.

Data Protection

SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor

Abstract

Extracted data

SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor

Abstract

Extracted data

Related items

Related items